Emergent BioSolutions Inc.

Headquartered in Gaithersburg, Maryland, Emergent BioSolutions operates as a life sciences company focused on preparedness and response solutions for public health threats, including accidental, deliberate, and naturally occurring biological and infectious disease events. The company manufactures and commercializes a portfolio of vaccines, antitoxins, and therapeutics targeting high-consequence pathogens and medical emergencies. Its commercial product portfolio includes NARCAN Nasal Spray for opioid overdose treatment, anthrax vaccines and therapeutics (BioThrax, Anthrasil, Raxibacumab, CYFENDUS), smallpox vaccines and treatments (ACAM2000, TEMBEXA), and vaccines for travel-related diseases including cholera (Vaxchora) and typhoid fever (Vivotif). Additional marketed products include Ebanga for Ebola treatment, botulism antitoxin, and auto-injectors for nerve agent exposure.

The company operates through two primary business segments: biodefense/public health products and contract development and manufacturing services. The biodefense segment generates revenue from sales of vaccines, immunotherapies, and therapeutics, with significant exposure to government procurement contracts and public health stockpiling programs. The contract manufacturing division provides drug substance and product manufacturing, packaging, analytical development, and technology transfer services to external clients. The company maintains development programs for vaccines targeting Lassa fever, Marburg virus disease, and Sudan virus disease, among others.